T0	KEYPHRASE-NOTYPES 0 3	LNB
T1	KEYPHRASE-NOTYPES 16 39	dangerous manifestation
T2	KEYPHRASE-NOTYPES 43 55	Lyme disease
T3	KEYPHRASE-NOTYPES 70 99	early antimicrobial treatment
T4	KEYPHRASE-NOTYPES 120 128	majority
T5	KEYPHRASE-NOTYPES 132 140	patients
T6	KEYPHRASE-NOTYPES 142 158	persistent forms
T7	KEYPHRASE-NOTYPES 186 196	mechanisms
T8	KEYPHRASE-NOTYPES 208 219	chronic LNB
T9	KEYPHRASE-NOTYPES 224 246	persistent forms
T10	KEYPHRASE-NOTYPES 250 254	Lyme
T11	KEYPHRASE-NOTYPES 268 276	Patients
T12	KEYPHRASE-NOTYPES 286 305	late manifestations
T13	KEYPHRASE-NOTYPES 309 311	LB
T14	KEYPHRASE-NOTYPES 336 344	response
T15	KEYPHRASE-NOTYPES 348 355	therapy
T16	KEYPHRASE-NOTYPES 361 382	incomplete resolution
T17	KEYPHRASE-NOTYPES 384 394	Persistent
T18	KEYPHRASE-NOTYPES 404 413	infection
T19	KEYPHRASE-NOTYPES 423 456	prolonged antimicrobial treatment
T20	KEYPHRASE-NOTYPES 475 506	controversial clinical efficacy
T21	KEYPHRASE-NOTYPES 508 524	Recent evidences
T22	KEYPHRASE-NOTYPES 542 563	antibiotic resistance
T23	KEYPHRASE-NOTYPES 572 584	reoccurrence
T24	KEYPHRASE-NOTYPES 588 590	LB
T25	KEYPHRASE-NOTYPES 611 634	biofilm-like aggregates
T26	KEYPHRASE-NOTYPES 675 707	adverse environmental conditions
T27	KEYPHRASE-NOTYPES 709 745	Several promising FDA-approved drugs
T28	KEYPHRASE-NOTYPES 770 802	excellent antipersister activity
T29	KEYPHRASE-NOTYPES 816 827	combination
T30	KEYPHRASE-NOTYPES 840 843	use
T31	KEYPHRASE-NOTYPES 847 867	monotherapy regimens
T32	KEYPHRASE-NOTYPES 877 895	poor effectiveness
T33	KEYPHRASE-NOTYPES 902 908	notion
T34	KEYPHRASE-NOTYPES 930 951	careful consideration
T35	KEYPHRASE-NOTYPES 960 979	clinical management
T36	KEYPHRASE-NOTYPES 983 995	Lyme Disease
T37	KEYPHRASE-NOTYPES 999 1004	order
T38	KEYPHRASE-NOTYPES 1016 1039	long-term complications
